TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03973112
Drug: HLX10 3mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-PD-1
Study: NCT03973112
Drug: HLX04 5mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-VEGF, a biosimilar to Avastin
Study: NCT03973112
Drug: HLX04 10mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-VEGF, a biosimilar to Avastin
Study: NCT02735421
Drug: ABPO Forte Gel
Normalized name: Carni Q-Gel Forte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants applied Adapalene 0.3% - Benzoyl peroxide (BPO) 2.5% gel (ABPO Forte) topically to the affected areas once daily for 24 weeks in Part 1 and for 48 weeks in Part 2.
Study: NCT01097018
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m2 BID/ Days 1-14
Study: NCT01097018
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 pill daily x 21 days
Study: NCT00625859
Drug: GSK189075
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK189075 will be available as film-coated tablets with a dose of 250 milligrams.
Study: NCT00625859
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets will be given to subjects.
Study: NCT02246673
Drug: RDEA3170 15 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02246673
Drug: RDEA3170 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02246673
Drug: RDEA3170 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02246673
Drug: RDEA3170 5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02735421
Drug: Vehicle gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants applied placebo matched to ABPO Forte gel topically to the affected areas once daily for 24 weeks in Part 1 and 48 weeks in Part 2.
Study: NCT02962245
Drug: regular treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: such as 5-ASA,immunomodulating/suppressive agents or Anti-TNF therapy
Study: NCT02359032
Drug: ASP6858
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT02359032
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT03429738
Drug: Ibuprofen/Pseudoephedrine HCl 200/30 mg Film-Coated Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental drug
Study: NCT03429738
Drug: RhinAdvil Rhume 200 mg/30 mg Film-Coated Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Comparator
Study: NCT01698203
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the placebo group, an initial bolus of saline 9 ‰ to a volume of 0.1 ml / kg will first be administered to the patient directly to the catheter. The patient will then continuous administration of saline 9 ‰ during the first 48 postoperative hours, using a diffuser extensible elastomeric ™ Easypump a volume of 400 mL to 460 mL filled of this solution, a flow rate of 9.53 ml / hour.
Study: NCT00849862
Drug: Keppra®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg Tablet
Study: NCT01048398
Drug: remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intervention: intravenous paracetamol 1g and remifentanil 1mg/100ml in 100ml of 0.9% saline.
Study: NCT01861665
Drug: Marcaine- 0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marcaine 0.25% administered pre-incision.
Study: NCT01861665
Drug: Marcaine 0.25%.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marcaine 0.25% administered post-incision.
Study: NCT01707953
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule to mimic midodrine
Study: NCT02549989
Drug: LY3023414
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrolled patients will take LY3023414 200 mg orally twice a day. Each cycle will be 21 days in duration. Patients will receive study treatment until disease progression, intolerable toxicity, elective withdrawal from the study, study completion, or study termination
Study: NCT03183765
Drug: Measles-Mumps-Rubella Vaccine
Normalized name: MEASLES/MUMPS/RUBELLA VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMR vaccine will be injected 0.5 ml into the largest wart at 2-week intervals until complete clearance was achieved or for a maximum of 3 treatments.~Response to treatment will be evaluated 1 month after the last session by decrease in the size of warts, decrease in the number of warts and photographic comparison. The clinical response was graded into complete (complete cure), partial (if there was a decrease in the size and\\or a decrease in the total number of warts), and no response (no change in size and number of warts).
Study: NCT00002798
Drug: therapeutic hydrocortisone
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002798
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT
Study: NCT00002798
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01333722
Drug: Hydrocodone/Acetaminophen Extended Release
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01333722
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet
Study: NCT04587206
Drug: CKD-828, D097, D337
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD, PO
Study: NCT01433510
Drug: Grazax
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet/day - pre and co-seasonal
Study: NCT00699062
Drug: singular
Normalized name: ALCOHOL 70 mL in 100 mL TOPICAL CLOTH [Singular Wipes]
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants randomized into this arm will receive singular 10mg q.n. plus combine therapy with inhaled ICS+LABA
Study: NCT00699062
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants allocated into this arm will receive placebo 10mg,q.n plus combine therapy with inhaled ICS+LABA
Study: NCT00003846
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00784368
Drug: ITCZ Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITCZ syrup product containing ITCZ 10 mg per ml in dose range of 20 ml to 40 ml daily for 7 days up to 12 weeks
Study: NCT00784368
Drug: ITCZ-IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg IV twice daily for 2 days and once daily for the next 1 to 12 days
Study: NCT01602250
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 8 mg/min ropivacaine 8 mg/min
Study: NCT01602250
Drug: Intralipid®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 8 mg/min ropivacaine 8 mg/min Intralipid® 120 ml in one min
Study: NCT00405873
Drug: AMT2003
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02457650
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: On days -7 through -6, Cyclophosphamide 60mg/kg/day IV will be infused over 60 minutes.
Study: NCT02727322
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01356862
Drug: PLACEBO
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONE INJECTION OF PLACEBO 10 TO 7 DAYS BEFORE SURGERY
Study: NCT01470131
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT01343745
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: pressurised metered dose inhaler
Study: NCT00959426
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be given placebo or PF-04620110. Anticipated total daily doses for Cohorts A, B, C, D, E, F and G are 1, 3, 5, 10 and 20 mg. In each Cohort 9 subjects will receive active treatment and 3 will receive placebo for 14 days. Doses shown may be adjusted upwards or downwards and may be adjusted to include intermediate doses during the study based on ongoing safety, tolerability and PK results, but will not be projected to exceed established PK stopping criteria.
Study: NCT00913510
Drug: Anticholinergic medication
Normalized name: Anticholinergics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticholinergic medication according to clinical practice and investigator´s judgement, either started at screening visit or continued from before study start, i.e. Drug.
Study: NCT02329743
Drug: RX-10045
Normalized name: BARRIER,SENSURA COLOPLAST #10045
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical therapy
Study: NCT00856609
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05524077
Drug: Anti-arrhythmic Drugs (AADs)
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care usually encompasses patients who have not previously had AADs, being commenced on sotalol 80mg twice/day. Lower doses may be initiated by treating doctor, as clinically indicated. If there is contraindication to sotalol, another beta-blocker may be initiated using standard doses. Clinicians may consider alternative AADs if there is contraindication to beta-blockers. Doses would be up titrated to the maximal tolerated amount.~For patients already on an AAD, amiodarone would usually be added, as per VANISH trial.~They will receive a loading dose 400mg twice/day for 2 weeks, followed by 400mg/day for 4 weeks and 200mg/day thereafter. Patients who have failed amiodarone dose \<300mg/day will receive a repeat loading dose of 400mg twice/day for 2 weeks, followed by 400mg/day for 1 week, and 300mg/day thereafter.~If the treating doctor decides to do a CA for VT, the occurrence and timepoint of cross-over will be recorded. Cross-over is estimated to be \<2% (VANISH trial).
Study: NCT02605356
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00185237
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch
Study: NCT00473889
Drug: Comparator: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: vorinostat 400 mg placebo capsules once daily. Up to 6 months of treatment
Study: NCT03063476
Drug: C-13 labeled Lysine
Normalized name: Urea C 13
DrugBank: Urea C-13 (DB09510)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Carbon-13 is a stable naturally occurring heavy isotope of carbon. Inclusion of a 13C label on lysine allows for subsequent differentiation between endogenous and exogenous lysine and 2-AAA for calculation of clearance and excretion of the lysine bolus.
Study: NCT03063476
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Because patients will have multiple blood draws during the course of the study, subjects will have an IV placed to reduce the number of needle sticks. To keep the vein open for blood collections, we will infuse Normal (0.9%) Saline (NS) at a rate of approximately 10ml/hr in order to keep the line open.
Study: NCT04365686
Drug: Ketofol as induction agent
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who received propofol (1mg/kg) plus ketamine (0.5mg/kg) at the induction of general anesthesia
Study: NCT03273881
Drug: glucose solution and Insulin
Normalized name: glucose Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women in group 1, will receive intravenous saline solution boosted with 5% glucose combined with 8 units of insulin at a rate of 125mL/h. The desirable intrapartum glucose level will be 70 to 100 mg/dL. Glucose levels will be checked hourly.~Glucose level between 100-140 mg/dL will be treated with additional intravenous insulin, 1 units/hour.~Glucose level between 141-160 mg/dL will be treated with intravenous insulin, 2 units/hour. Additionally, the 5% glucose solution will be substitute with lactated Ringer's solution.~Glucose level between 161-200 mg/dL will be treated with intravenous insulin, 4 units/hour.~Glucose level above 200 mg/dL will be treated with intravenous insulin, 6 units/hour.
Study: NCT03273881
Drug: glucose solution only
Normalized name: glucose Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women in group 2, will receive intravenous saline solution boosted with 5% glucose only, at a rate of 125mL/h. Women in this group will be treated similar to group 1 if glucose levels crossed over 100 mg/dL.
Study: NCT02652910
Drug: CD19.CAR-T cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retroviral vector-transduced autologous T cells to express CD19-specific CARs
Study: NCT02433912
Drug: 750 mg paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic analgesics consisting of 750 mg of paracetamol was taken every six hours for four days
Study: NCT01960283
Drug: Methotrexate (Novatrex ®) + anti-H1
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (Novatrex ®) tablets 2.5 mg methotrexate 0.2 mg/kg/week as a single dose, orally for 8 weeks.~After 8 weeks, if the treatment is still not efficient, the dose will be increased to 0.25 mg/kg/week and continued until W18.~For anti-H1 treatment, the same molecules with the same dosage than before the recruitment will be continued, and methotrexate will be added in this group.
Study: NCT03812744
Drug: Placebo Oral Capsule [CEBOCAP]
Normalized name: Placebo Oral Capsule [CEBOCAP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silica Oxide
Study: NCT01960283
Drug: Placebo + anti-H1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: 0.2 mg / kg / week as a single dose, orally for 8 weeks. After eight weeks, if the patient is still very embarrassed, the dose is increased to 0.25 mg / kg / week in a weekly dose.~For anti-H1 treatment, the same molecules with the same dosage than before the recruitment will be continued, and the placebo of methotrexate will be added in this group.
Study: NCT00856635
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: injected daily subcutaneously
Study: NCT01533727
Drug: Autologous CIK Transfusion plus Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: vinorelbine 25-30mg/m2 d1, d8 q3w; DDP 75mg/m2 d1 q3w; pemetrexed 500mg/m2 d1 q3w; carboplatin AUC 5/6 q3w; CIK infusion D14 q3w
Study: NCT01533727
Drug: chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: vinorelbine 25-30mg/m2 d1, d8 q3w; DDP 75mg/m2 d1 q3w; pemetrexed 500mg/m2 d1 q3w; carboplatin AUC 5/6 q3w;
Study: NCT04393038
Drug: ABX464
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABX464 50mg QD for 28 days + Standard of Care
Study: NCT04393038
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 50mg QD for 28 days + Standard of Care
Study: NCT03325322
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00410189
Drug: ZD6474
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg by mouth daily for 28 Days.
Study: NCT03618667
Drug: GC1118
Approvals — FDA: no, EMA: no, PMDA: no
Description: GC1118 (4mg/kg) will be administered by IV infusion once per week for 4 weeks(28-day cycles) up to 6 cycles, or till progression or uncontrolled toxicity.
Study: NCT01673659
Drug: Placebo nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04462029
Drug: BR4002
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Administration to the T1 group: 5 mg of BR4002 (patch) will be attached using an applicator for 24 hours~* Administration to the T2 group: 5 mg of BR4002 (patch) will be attached without using an applicator for 24 hours
Study: NCT04462029
Drug: BR4002-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration to the R group: 5 mg of BR4002-1 (oral formulation) will be administered with 150 mL of water
Study: NCT00118274
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01206881
Drug: pegylated liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 mg/m2, IV, day 1 every 21 days, 4 cycles
Study: NCT02192567
Drug: DS-5573a
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Step 1 of this study will use a starting intravenous (IV) dose of 0.1 mg/kg. Eight dose levels are planned, level 1: 0.1 mg/kg, level 1.5: 0.1 mg/kg, 0.3 mg/kg, level 2: 0.3 mg/kg, level 3: 1 mg/kg, level 4: 3 mg/kg, level 5: 10 mg/kg, level 6: 20 mg/kg, level 7: 30 mg/kg.~Step 2: 30 subjects will use the dose determined in Step 1.
Study: NCT01138085
Drug: GSK1120212
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEK inhibitor
Study: NCT01138085
Drug: GSK2141795
Approvals — FDA: no, EMA: no, PMDA: no
Description: AKT Inhibitor
Study: NCT02776046
Drug: Conventional FiO2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional FiO2 with a perioperative open lung strategy
Study: NCT03190798
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for Canagliflozin
Study: NCT03288454
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline for injection
Study: NCT00463086
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A self-administered dose of 5mg/kg of placebo (300mg if weight is more than or equal to 50kg and 200mg if weight is less than 50kg)
Study: NCT02137642
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double blind placebo will be delivered once by injection during study procedure.
Study: NCT01063348
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules taken in same amount of pills as the active medication.
Study: NCT02141672
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04301661
Drug: Switch
Normalized name: Universal Footswitch Covers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants who are planning to switch from abacavir/lamivudine as part of standard HIV care will change therapy to per the discretion of their HIV provider.
Study: NCT02172391
Drug: Placebo inhalation powder capsules
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01103440
Drug: Antiplatelet Therapy (ASA, Clopidogrel)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antiplatelet PCI treatment
Study: NCT00114127
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60mg placebo 1x per day
Study: NCT03072043
Drug: APR-246
Normalized name: PrameGel Reformulated Apr 2012
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 1b: Dose escalation of APR-246 via intravenous (IV) infusion, with starting dose of 50 mg/kg lean body weight (LBW). Phase 2: APR-246 at maximum tolerated dose (MTD).
Study: NCT01466205
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150mls of saline is administered over 30 minutes at approximately 11:00AM on each of three consecutive days of administration. Additional saline will be co-administered to ensure hydration.
Study: NCT04571060
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One dose of matching placebo
Study: NCT02186483
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin, 20 mg, once daily
Study: NCT02186483
Drug: Metformin and Rosuvastatin
Normalized name: rosuvastatin and ezetimibe
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Metformin, 1000mg, once daily Rosuvastatin, 20mg, once daily
Study: NCT01736033
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet(0.2mg) orally q.d.
Study: NCT03040128
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: high-dose, intravenous minocycline
Study: NCT03328832
Drug: Floseal®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Floseal® (Hemostatic matrix, 10ml, Baxter) was applied on potential bleeding sites: the femoral insertion of the posterior cruciate ligament, the lateral genicular artery after resection of the meniscus, the posterior capsule of the knee joint, the bony surfaces not covered by the implant as well as the pinholes (femur and tibia). The entire content of a 10 mL vial containing the active product (Floseal®) was used. The HM remained in place for 3 minutes and was then gently rinsed from the knee as recommended by the manufacturer (Baxter)
Study: NCT00405730
Drug: Nepafenac 1mg/ml eye drops, suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop in the study eye 3 times daily for 23 days
Study: NCT00405730
Drug: Ketorolac Trometamol 5 mg/ml eye drops, solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop in the study eye 3 times daily for 23 days
Study: NCT03192137
Drug: ISV-305
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone in DuraSite® 2 twice daily for 16 days
Study: NCT02799589
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1mcg/kg over 1 min followed by an infusion (0.05-0.5 mcg/kg/min)
Study: NCT03332576
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PO BID
Study: NCT02574130
Drug: Amikacin
Normalized name: amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg, nebulizer, every 12 hours, 10 days
Study: NCT01060254
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form=solution for injection, route=Subcutaneous injection. One injection of matching placebo every 28 days for up to 12 wks
Study: NCT01830348
Drug: DSC127
Approvals — FDA: no, EMA: no, PMDA: no
Description: DSC127 0.03%, daily topical application to diabetic foot ulcer for a period of up to 28 days or until ulcer closure, whichever is sooner
Study: NCT01830348
Drug: placebo vehicle gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01653444
Drug: GC1119
Approvals — FDA: no, EMA: no, PMDA: no
Description: biweekly, IV infusion
Study: NCT02574130
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 4 ml, nebulizer, every 12 hours, 10 days
Study: NCT01949129
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: as part of conditioning 60 mg/kg BW 2 days or as GvHD Prophylaxis 50mg/kg BW/d 2 days with Mesna
Study: NCT01949129
Drug: Grafalon
Approvals — FDA: no, EMA: no, PMDA: no
Description: MD: 15mg/kg BW/d 3 days MMD: 10mg/kg BW/d 3 days
Study: NCT02012218
Drug: ADT
Normalized name: Radtue
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01371058
Drug: policosanol plus dual antiplatelet
Normalized name: POLICOSANOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: aspirin 300 mg/d for 1 month followed by 100 mg/d chronically； clopidogrel 75 mg/d for at least 1 year policosanol 40mg/d for 6 months
Study: NCT03186625
Drug: Placebo Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo granule has the same as Compound Panax Notoginseng Granule in the appearance, shape,colour,taste,frequency and duration.
Study: NCT02171143
Drug: ASP2409
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous (IV)